URGN Earnings & Financial Statements
UroGen Pharma Ltd.
$36.79
-$3.92(-9.62%)
43
Overall
40
Value
30
Tech
60
Quality
Market Cap
$1.99B
Volume
1.18M
52W Range
$15.86 - $50.81
Target Price
$60.00
URGN earnings and financial statements: UroGen Pharma Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
URGN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M |
| EBITDA | -$135.18M | -$111.64M | -$80.89M | -$97.77M | -$107.60M |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M |
| EPS (diluted) | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | $119.75M |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | $111.33M |
| Shareholders’ equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | $8.41M |
| Cash and equivalents | $110.75M | $171.99M | $95.00M | $55.41M | $44.36M |
| Long-term debt | $122.21M | $121.73M | $98.55M | $99.12M | $398.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -$84.89M |
| Capital expenditure | -$289.0K | -$295.0K | -$194.0K | -$254.0K | -$752.0K |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -$85.64M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | URGN | $36.79 | -9.6% | 1.18M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |